Carlos Arteaga awarded $600,000 to study breast cancer therapy resistance

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The Susan G. Komen organization has awarded a $600,000 research grant to Carlos Arteaga, director of the Harold C. Simmons Comprehensive Cancer Center and associate dean of oncology programs at UT Southwestern Medical Center.

The grant to Arteaga is part of a $62 million investment by the Komen organization for research on drug resistance, triple negative breast cancer, and new treatments such as immunotherapies, as well as funding to reduce cancer health disparities.

Arteaga will study how estrogen receptor-positive breast cancers become hormone-independent and develop resistance to current anti-estrogen therapies. The research could lead to more precise treatment plans for breast cancer patients, potentially involving combinations of drug therapies to prevent the development of drug resistance.

Table of Contents

YOU MAY BE INTERESTED IN

I have spent over 20 years running a tumor imaging metrics core at an academic cancer center. In that time, I have watched clinical trial enrollment concentrate at a relatively small number of flagship academic institutions. Unfortunately, trials do not propagate well to the community sites where most patients prefer to receive care. The explanations usually offered for why this happens have never fully accounted for what I observed.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login